Back to top
more

Charles River Laboratories International (CRL)

(Delayed Data from NYSE)

$205.27 USD

205.27
595,091

+3.94 (1.96%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $205.42 +0.15 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (148 out of 251)

Industry: Medical Services

Better trading starts here.

Zacks News

Charles River (CRL) to Report Q3 Earnings: What's in the Cards?

Robust demand for research models and the Vigene Biosciences buyout are likely to have contributed to growth for Charles River (CRL).

Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Charles River (CRL) to Offer Cryo-EM Capabilities With New Pact

Charles River's (CRL) recent partnership will enable the company to improve drug discovery projects by allowing structure-based design for a greater portfolio of targets.

Here's Why You Should Invest in Charles River (CRL) Now

Investors are optimistic about Charles River (CRL) on solid second-quarter performance and bullish 2021 guidance.

Why Is Charles River (CRL) Up 9.5% Since Last Earnings Report?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Charles River (CRL) at a 52-Week High: What's Driving It?

Charles River (CRL) ended the second quarter on a strong note with solid performance by the RMS, DSA and Manufacturing Support arms driving the top line.

MODV or CRL: Which Is the Better Value Stock Right Now?

MODV vs. CRL: Which Stock Is the Better Value Option?

Charles River (CRL) Q2 Earnings Beat Estimates, 2021 View Up

Robust performance by all three segments drove Charles River's (CRL) revenues in the second quarter.

Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates

Charles River (CRL) delivered earnings and revenue surprises of 9.21% and 5.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Charles River (CRL) Q2 Earnings to Mirror Broad-Based Demand

Charles River's (CRL) biotech clients are likely to have benefited from a robust funding environment in Q2.

Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Charles River (CRL) at a 52-Week High: What's Driving It?

Strong performance by the RMS, DSA and Manufacturing segments is driving the top line for Charles River (CRL).

Sweta Killa headshot

10 Top-Ranked Stocks Powering S&P 500 ETF

The S&P 500 has been outperforming this year due to the strength in value and cyclical stocks, which were battered last year in the pandemic.

Charles River (CRL) Advances in Gene Therapy With Vigene Buyout

The consolidation between Charles River (CRL) and Vigene is set to establish an end-to-end, gene-modified cell therapy solution in the United States.

What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?

Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Duke Energy (DUK) Brand Starts Building 250MW Solar Project

Duke Energy (DUK) announces the 250-MW Pisgah Ridge Solar project will supply power to three corporations, once its construction is completed by 2022-end.

Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates

Charles River (CRL) delivered earnings and revenue surprises of 15.53% and 3.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Neena Mishra headshot

ETF Strategies to Hedge Against Inflation

Here are some ways to protect your portfolio from rising inflation.

Teladoc (TDOC) Q4 Loss Widens, Revenues Surpass Estimates

Teladoc's (TDOC) Q4 earnings result reflects revenue gains, more than offset by flared-up expenses.

Company News for Feb 18, 2021

Companies in the news are: CRL, VIR, LODE, CLPS

Charles River Laboratories (CRL) Beats Q4 Earnings and Revenue Estimates

Charles River (CRL) delivered earnings and revenue surprises of 12.74% and 4.63%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Charles River Laboratories (CRL) Reports Next Week: Wall Street Expects Earnings Growth

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is a Beat in the Cards for CVS Health (CVS) in Q4 Earnings?

Through November and December, the resurgence of new COVID-19 cases might have resulted in more COVID-19 tests conducts by CVS Health (CVS).